Skip to content

    Granules India

    GRANULESNeutral
    Healthcare·24 Jan 2025
    Management Summary

    Granules India reported a mixed Q3 FY25, with revenue slightly down year-on-year but showing strong sequential growth. Gross margins improved significantly year-on-year, though EBITDA margins were impacted by one-off remediation and air freight costs related to the USFDA's 'Official Action Indicated' (OAI) classification for its Gagillapur facility. The company is actively addressing the OAI with 90% of CAPAs completed and is confident in its long-term growth trajectory, driven by new product launches, capacity expansion at Genome Valley, and focus on therapeutic areas like CNS ADHD and Oncology.

    Highlights

    8
    • Q3 FY25 Revenue stood at INR 11,377 million, a 2% decline YoY but an 18% increase QoQ.

    • Gross Margin for Q3 FY25 was 61.7%, up 474 bps YoY, but down 20 bps QoQ.

    • EBITDA for Q3 FY25 was INR 2,303 million (20.2% of sales), down 144 bps YoY and 80 bps QoQ.

    • R&D spend for Q3 FY25 was INR 568 million, compared to INR 468 million in Q3 FY24.

    • Net debt increased to INR 8,289 million from INR 7,973 million in Q2 FY25.

    • USFDA inspection of Gagillapur facility resulted in an 'Official Action Indicated' (OAI) classification; 90% of CAPAs are completed.

    • Long-term revenue CAGR is targeted at 'around 20% plus'.

    • Phase I of the new Genome Valley (GLS) formulation facility with 2.5 billion doses capacity has been commissioned.

    Concerns

    2
    • USFDA 'Official Action Indicated' (OAI) classification for Gagillapur facility

    • Uncertainty regarding USFDA re-inspection timeline for Gagillapur facility

    What Changed3

    vs Q4 FY25

    Tone shiftGood → Cautious but BullishGuidance items11 → 9 (-2)Risks discussed4 → 5 (+1)

    Key financials

    Single quarter

    07 metrics
    1. 01Revenue11,377 Mn-1.5%YoY
    2. 02Gross Margin61.7%
    3. 03EBITDA2,303 Mn-8.1%YoY
    4. 04EBITDA Margin20.2%
    5. 05R&D Spend568 Mn

    Guidance & targets

    9
    CategoryTargetPriority
    Revenue
    Revenue CAGR
    around 20% plus
    Medium
    Revenue
    Revenue Growth
    something like a 20% growth
    Medium
    Margin
    EBITDA Margin Range
    20%, 22% margin range
    Medium
    Capex
    Capex
    INR500-odd crores
    Low
    Capacity
    GLS Phase I Capacity
    2.5 billion doses
    High
    Capacity
    GLS Phase II Capacity
    additional 7.5 billion dose capacity
    High
    Capacity
    GLS Total Capacity
    about 10 billion capacity
    High
    Other
    GLS European Inspection
    late March or early April
    High
    Other
    GLS US Inspection
    6 months, 9 months, whatever
    Medium

    Risks & concerns

    7
    RiskSeverity

    USFDA 'Official Action Indicated' (OAI) classification for Gagillapur facility

    OAI impacts review of pending submissions for new product approvals from the site until resolved, though existing product manufacturing/distribution is not impacted.Management acknowledged

    high

    One-off costs related to remediation, supply disruption (air freight), and professional expenses

    These costs, quantified at ~$3 million for Q3 FY25, negatively impacted Q3 EBITDA margins, with ~50% expected to recur in Q4 FY25 at a reduced level.Management acknowledged

    medium

    Uncertainty regarding USFDA re-inspection timeline for Gagillapur facility

    Management is planning to request re-inspection but cannot provide specific dates, leading to uncertainty about new product approvals from the site.Management acknowledged

    high

    High inventory levels for paracetamol due to Red Sea issues and past customer stocking

    This situation is expected to lead to flat performance for the paracetamol API business in Q4 FY25, though FY26 looks better.Management acknowledged

    medium

    Potential implications of Trump presidency on the pharma industry

    Management views the administration as 'industry friendly' and expects 'a lot of positivity' for the pharma industry, with the company's US facility being an advantage.Analyst downplayed

    low

    Areas of Evasion(2)

    • Specific FY25 revenue/EBITDA guidance due to OAI
    • Firm timeline for FDA re-inspection

    Q&A highlights

    3

    “If everything is status quo, and it is OAI, we will not get approval since that is clear, new approval. So the growth has to come from existing products, increasing market in Europe and other places and mainly from the US operations and production from GLS. So we cannot put a number today. But definitely, when you see CAGR, we will continue to maintain it even though there are blips. So CAGR will definitely be around 20% plus.”

    Directly addresses the immediate financial impact of the OAI, with management acknowledging inability to give specific FY25 guidance but reiterating long-term growth.

    asked by Tushar Manudhane

    2 min read6 chapters

    Detailed Narrative

    01

    USFDA Gagillapur Facility OAI & Remediation Efforts

    The USFDA classified the inspection of Granules' Gagillapur finished dosage facility (August 26 - September 6) as 'Official Action Indicated' (OAI), following six Form 483 observations. The company has undertaken a proactive and comprehensive remediation plan, with 90% of Corrective and Preventive Actions (CAPAs) completed and the remainder on track for closure by March '25. Operations and dispatches resumed in October after a voluntary pause in September for risk assessment, and Granules is maintaining continuous communication with the FDA, including monthly progress updates.

    02

    Q3 FY25 Financial Performance Overview

    Granules India reported Q3 FY25 revenue of INR 11,377 million, a 2% decline year-on-year but an 18% improvement quarter-on-quarter. Gross margins expanded significantly to 61.7% in Q3 FY25, up 474 basis points year-on-year, driven by profitable sales growth of finished dosages. However, EBITDA for the quarter was INR 2,303 million (20.2% of sales), decreasing by 144 basis points year-on-year and 80 basis points quarter-on-quarter, primarily due to one-off📎 costs.

    03

    Impact of One-off Costs on Margins

    EBITDA margins in Q3 FY25 were impacted by approximately $3 million in one-off📎 expenses, including consultancy fees for remediation, failure-to-supply costs, and increased air freight charges. Management indicated that about 50% of these costs might recur in Q4 FY25, albeit at a reduced level. This explains the sequential decline in EBITDA margin despite strong gross margin performance.

    04

    Growth Strategy and Product Pipeline

    The company's growth trajectory remains robust and diversified, with a focus on new product launches from its GPI site for the US market, particularly in the CNS ADHD segment. Granules has 83 ANDAs in the US (15 awaiting approval), 12 applications in Europe (4 awaiting approval), and 15 applications in the rest of the world (8 awaiting approval). R&D spend for Q3 FY25 was INR 568 million, up from INR 468 million in Q3 FY24, reflecting continued investment in its pipeline, including oncology and antidiabetic segments.

    05

    Capacity Expansion at Genome Valley (GLS)

    Granules' new formulation facility at Genome Valley under Granules Life Sciences is progressing well. Phase I, with a capacity of 2.5 billion doses, has been commissioned, and commercial dispatches of monograph products have commenced. Phase II, adding an additional 7.5 billion dose capacity, is expected to be commissioned by Q4 FY25, with validation activities slated for Q1 FY26, bringing the total planned capacity to 10 billion doses. The company expects a European inspection for this facility in late March or early April.

    06

    Capex and Debt Management

    Capex spend during Q3 FY25 was INR 1,335 million, primarily invested in Granules Life Sciences (INR 940 million). Year-to-date capex stands at INR 4,102 million, with INR 2,425 million for GLS. For FY26, the company estimates capex to be 'anywhere between INR500-odd crores.' Net debt increased slightly to INR 8,289 million in Q3 FY25 from INR 7,973 million in Q2 FY25, but management emphasized that they are not taking additional borrowings and cash flow from operations is managed well.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.